MindMed is a clinical-stage biopharmaceutical company dedicated to developing innovative psychedelic-inspired therapies for brain health disorders. Leveraging cutting-edge research, MindMed focuses on conditions such as anxiety, attention-deficit/hyperactivity disorder (ADHD), and autism spectrum disorder. Their robust pipeline includes MM-120, a proprietary form of LSD targeting generalized anxiety disorder, and MM-402, the R-enantiomer of MDMA, aimed at treating core symptoms of autism spectrum disorder. Committed to advancing mental health treatment, MindMed combines scientific expertise with a patient-centric approach to deliver transformative therapies that address significant unmet needs.